Noninvasive Markers of Functional Nausea in Children

Sponsor
Vanderbilt University Medical Center (Other)
Overall Status
Enrolling by invitation
CT.gov ID
NCT03593811
Collaborator
(none)
130
1
5
63.9
2

Study Details

Study Description

Brief Summary

The researchers propose to study how functional nausea in adolescents may be characterized noninvasively by the use of multichannel electrogastrogram (EGG) and magnetogastrogram (MGG) recordings.

Condition or Disease Intervention/Treatment Phase
  • Diagnostic Test: Questionnaires
  • Diagnostic Test: 4 channel electrogastrogram (EGG)
  • Diagnostic Test: 36 channel high resolution electrogastrogram (HR-EGG)
  • Diagnostic Test: Magnetogastrogram (MGG)
  • Diagnostic Test: Electrocardiogram (EKG)
  • Drug: Ondansetron
  • Drug: Cyproheptadine Oral Tablet
N/A

Detailed Description

Functional nausea (FN) is a GI disorder that affects millions of Americans, particularly adolescents, but diagnoses remain largely exclusionary relying on symptomology with an otherwise normal diagnostic workup.

Successful completion of the project could contribute to understanding the altered physiology of functional nausea (FN), to stratification of FN patients according to physiological and/or psychological phenotypes, to improve diagnosis and provide objective measures of nausea and to inform and guide treatment options.

The analysis of slow wave activity represents the first physiologically-quantifiable noninvasive assessment method for pathological processes associated with functional nausea in adolescents.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
130 participants
Allocation:
Non-Randomized
Intervention Model:
Parallel Assignment
Masking:
None (Open Label)
Primary Purpose:
Diagnostic
Official Title:
Noninvasive Markers of Functional Nausea in Children
Actual Study Start Date :
Aug 3, 2018
Anticipated Primary Completion Date :
Sep 1, 2023
Anticipated Study Completion Date :
Dec 1, 2023

Arms and Interventions

Arm Intervention/Treatment
Active Comparator: Healthy Controls

Healthy Volunteers with no known gastrointestinal complications will be given questionnaires and testing by electrogastrogram (EGG) and/or magnetogastrogram (MGG) after an overnight fast to determine nausea parameters. They will also have a electrocardiogram (EKG) and do some testing after being fed a protein bar.

Diagnostic Test: Questionnaires
Patients will be provide answers to one or more of the following: Rome III criteria, BARF pictorial scale, Nausea Severity scale, Children's Somatization Inventory, State-Trait Anxiety Inventory, Functional Disability Inventory, and the Nausea Interference Scale.

Diagnostic Test: 4 channel electrogastrogram (EGG)
EGG is a non-invasive technique for recording gastric myoelectrical activity using cutaneous electrodes placed on the abdominal skin over the stomach.

Diagnostic Test: 36 channel high resolution electrogastrogram (HR-EGG)
HR- EGG utilizes an array of electrodes to estimate the direction and speed of gastric slow-waves using cutaneous electrodes placed on the abdominal skin over the stomach.

Diagnostic Test: Magnetogastrogram (MGG)
MGG measures spatiotemporal properties of magnetic fields from the gastric slow wave and allows characterization of the propagation of the gastric slow wave in addition to evaluation of its frequency and power distribution.
Other Names:
  • SQUID magnetometer
  • Diagnostic Test: Electrocardiogram (EKG)
    Electrocardiography is the process of recording the electrical activity of the heart over a period of time using electrodes placed on the skin

    Active Comparator: Non-nauseated

    Functional nausea patients with a score of 0-2 on the BARF (BAxter Retching Faces) scale will be given questionnaires and testing by EGG and/or MGG after an overnight fast to determine nausea parameters. They will also have a EKG and do some testing after being fed a protein bar.

    Diagnostic Test: Questionnaires
    Patients will be provide answers to one or more of the following: Rome III criteria, BARF pictorial scale, Nausea Severity scale, Children's Somatization Inventory, State-Trait Anxiety Inventory, Functional Disability Inventory, and the Nausea Interference Scale.

    Diagnostic Test: 4 channel electrogastrogram (EGG)
    EGG is a non-invasive technique for recording gastric myoelectrical activity using cutaneous electrodes placed on the abdominal skin over the stomach.

    Diagnostic Test: 36 channel high resolution electrogastrogram (HR-EGG)
    HR- EGG utilizes an array of electrodes to estimate the direction and speed of gastric slow-waves using cutaneous electrodes placed on the abdominal skin over the stomach.

    Diagnostic Test: Magnetogastrogram (MGG)
    MGG measures spatiotemporal properties of magnetic fields from the gastric slow wave and allows characterization of the propagation of the gastric slow wave in addition to evaluation of its frequency and power distribution.
    Other Names:
  • SQUID magnetometer
  • Diagnostic Test: Electrocardiogram (EKG)
    Electrocardiography is the process of recording the electrical activity of the heart over a period of time using electrodes placed on the skin

    Active Comparator: Mildly nauseated

    Functional nausea patients with a score of 3-4 on the BARF (BAxter Retching Faces) scale will be given questionnaires and testing by EGG and/or MGG after an overnight fast to determine nausea parameters. They will also have a EKG and do some testing after being fed a protein bar.

    Diagnostic Test: Questionnaires
    Patients will be provide answers to one or more of the following: Rome III criteria, BARF pictorial scale, Nausea Severity scale, Children's Somatization Inventory, State-Trait Anxiety Inventory, Functional Disability Inventory, and the Nausea Interference Scale.

    Diagnostic Test: 4 channel electrogastrogram (EGG)
    EGG is a non-invasive technique for recording gastric myoelectrical activity using cutaneous electrodes placed on the abdominal skin over the stomach.

    Diagnostic Test: 36 channel high resolution electrogastrogram (HR-EGG)
    HR- EGG utilizes an array of electrodes to estimate the direction and speed of gastric slow-waves using cutaneous electrodes placed on the abdominal skin over the stomach.

    Diagnostic Test: Magnetogastrogram (MGG)
    MGG measures spatiotemporal properties of magnetic fields from the gastric slow wave and allows characterization of the propagation of the gastric slow wave in addition to evaluation of its frequency and power distribution.
    Other Names:
  • SQUID magnetometer
  • Diagnostic Test: Electrocardiogram (EKG)
    Electrocardiography is the process of recording the electrical activity of the heart over a period of time using electrodes placed on the skin

    Active Comparator: Moderately nauseated

    Functional nausea patients with a score of 5-6 on the BARF (BAxter Retching Faces) scale will be given questionnaires and testing by EGG and/or MGG after an overnight fast to determine nausea parameters. They will also have a EKG and do some testing after being fed a protein bar.

    Diagnostic Test: Questionnaires
    Patients will be provide answers to one or more of the following: Rome III criteria, BARF pictorial scale, Nausea Severity scale, Children's Somatization Inventory, State-Trait Anxiety Inventory, Functional Disability Inventory, and the Nausea Interference Scale.

    Diagnostic Test: 4 channel electrogastrogram (EGG)
    EGG is a non-invasive technique for recording gastric myoelectrical activity using cutaneous electrodes placed on the abdominal skin over the stomach.

    Diagnostic Test: 36 channel high resolution electrogastrogram (HR-EGG)
    HR- EGG utilizes an array of electrodes to estimate the direction and speed of gastric slow-waves using cutaneous electrodes placed on the abdominal skin over the stomach.

    Diagnostic Test: Magnetogastrogram (MGG)
    MGG measures spatiotemporal properties of magnetic fields from the gastric slow wave and allows characterization of the propagation of the gastric slow wave in addition to evaluation of its frequency and power distribution.
    Other Names:
  • SQUID magnetometer
  • Diagnostic Test: Electrocardiogram (EKG)
    Electrocardiography is the process of recording the electrical activity of the heart over a period of time using electrodes placed on the skin

    Active Comparator: Severely nauseated

    Functional nausea patients with a score of 7-9 on the BARF (BAxter Retching Faces) scale will be given questionnaires and testing by EGG and/or MGG after an overnight fast to determine nausea parameters. They will also have a EKG and do some testing after being fed a protein bar. Some patients will also be tested after receiving a one time dose of a 4mg or 8mg dependent upon age disintegrating tablet of ondansetron followed by a 2 day washout period prior to testing again after a 5 day maintenance dose of oral cyproheptadine 4mg twice a day.

    Diagnostic Test: Questionnaires
    Patients will be provide answers to one or more of the following: Rome III criteria, BARF pictorial scale, Nausea Severity scale, Children's Somatization Inventory, State-Trait Anxiety Inventory, Functional Disability Inventory, and the Nausea Interference Scale.

    Diagnostic Test: 4 channel electrogastrogram (EGG)
    EGG is a non-invasive technique for recording gastric myoelectrical activity using cutaneous electrodes placed on the abdominal skin over the stomach.

    Diagnostic Test: 36 channel high resolution electrogastrogram (HR-EGG)
    HR- EGG utilizes an array of electrodes to estimate the direction and speed of gastric slow-waves using cutaneous electrodes placed on the abdominal skin over the stomach.

    Diagnostic Test: Magnetogastrogram (MGG)
    MGG measures spatiotemporal properties of magnetic fields from the gastric slow wave and allows characterization of the propagation of the gastric slow wave in addition to evaluation of its frequency and power distribution.
    Other Names:
  • SQUID magnetometer
  • Diagnostic Test: Electrocardiogram (EKG)
    Electrocardiography is the process of recording the electrical activity of the heart over a period of time using electrodes placed on the skin

    Drug: Ondansetron
    Patients will be administered 4mg or 8 mg ondansetron dependent upon age in order to assess the effect of ondansetron on the symptoms of nausea and changes in slow wave dysrhythmias.

    Drug: Cyproheptadine Oral Tablet
    Patients will be prescribed a 5 day maintenance dose of cyproheptadine using dosing 4mg twice a day to examine the effects of pharmacological alteration of specific nausea pathways on gastric slow wave patterns in functional nausea patients

    Outcome Measures

    Primary Outcome Measures

    1. Percentage of Normal Slow Waves (PNSW) [6 months]

      Determine if there are differences in the slow wave activity in healthy versus disease stomach in the pediatric population. The percentage of normal slow waves (PNSW) will be used for comparison. PNSW is computed as the relative time of recording containing slow waves with a dominant frequency between 2-4 cpm from centrally-located EEG and MGG channels.

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    8 Years to 17 Years
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    Yes
    Inclusion Criteria:
    • children ages 8-17 with functional nausea

    • normal control participants ages 8-17 who have no known gastrointestinal complications

    Exclusion Criteria:
    • Those with claustrophobia who cannot lie still under the SQUID for the length of time required.

    • Normal participants with known intestinal complications

    • Patients with cyclic vomiting syndrome, gastroparesis, malignancy, primary eating disorders, pregnancy, or hyperglycemia

    • Morbid obesity (these patients are presumably unable to lie under the current generation of SQUID devices).

    • Patients with a history of cardiac arrhythmias or taking anticoagulants will be excluded

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Vanderbilt University Medical Center Nashville Tennessee United States 37212

    Sponsors and Collaborators

    • Vanderbilt University Medical Center

    Investigators

    • Principal Investigator: Alan Bradshaw, Ph.D., Vanderbilt University

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    Alan Bradshaw, Principal Investigator, Vanderbilt University Medical Center
    ClinicalTrials.gov Identifier:
    NCT03593811
    Other Study ID Numbers:
    • 162035
    First Posted:
    Jul 20, 2018
    Last Update Posted:
    Apr 4, 2022
    Last Verified:
    Apr 1, 2022
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    Yes
    Product Manufactured in and Exported from the U.S.:
    Yes
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Apr 4, 2022